VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

ASH 2020 | What does the future of amyloidosis treatment look like?

Efstathios Kastritis, MD, University of Athens School of Medicine, Athens, Greece, highlights the exciting updates in amyloidosis treatment presented at ASH 2020. Following the results of the ANDROMEDA study (NCT03201965) showing improvement in survival and quality of life regardless of the patient cardiac stage, daratumumab, a CD38 monoclonal antibody, is now expected to be approved as a frontline treatment in amyloidosis. Another agent, isatuximab, was also found to have an excellent safety profile and impressive hematologic response rates in this patient population. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter